Suppr超能文献

唾液腺导管癌颅内转移的雄激素剥夺治疗:病例报告

Androgen Deprivation Therapy for Intracranial Metastasis of a Salivary Duct Carcinoma: Case Report.

作者信息

Rösch Manuel, Bieg Christian, Savic Spasenija, Buess Martin

机构信息

Department of Medical Oncology, Basel University Hospital, Basel, Switzerland.

Radiology Department, St. Claraspital, Basel, Switzerland.

出版信息

Case Rep Oncol. 2023 Feb 23;16(1):109-115. doi: 10.1159/000529470. eCollection 2023 Jan-Dec.

Abstract

Salivary duct carcinoma (SDC) is a rare subtype of salivary cancers associated with androgen receptor and human epidermal growth factor receptor 2 (HER2/neu) overexpression. It shows a high propensity to give rise to distant metastases mainly to the lung, the bone, and the liver. Intracranial metastases are rare. We report the case of a 61-year-old male patient with SDC developing intracranial metastases. Unresponsive to radiotherapy and anti-HER/neu targeted therapy the intracranial metastases showed a very good partial remission to androgen deprivation therapy with goserelin acetate. This case demonstrates the potential of a highly targeted therapy with a relatively cheap and well-known drug in a patient with a rare disease without other good therapeutic options, which is a good example of modern, personalized medicine.

摘要

涎腺导管癌(SDC)是涎腺癌的一种罕见亚型,与雄激素受体及人表皮生长因子受体2(HER2/neu)过表达相关。它极易发生远处转移,主要转移至肺、骨和肝脏。颅内转移罕见。我们报告一例61岁男性涎腺导管癌患者发生颅内转移的病例。该患者对放疗及抗HER/neu靶向治疗无反应,而醋酸戈舍瑞林进行雄激素剥夺治疗后,颅内转移灶出现了非常好的部分缓解。本病例显示,对于一种罕见病且没有其他良好治疗选择的患者,使用一种相对便宜且知名的药物进行高度靶向治疗具有潜力,这是现代个性化医疗的一个良好范例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ac9/9950966/54a45acd6af9/cro-2023-0016-0001-529470_F1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验